Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO) (Paris:GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis
GeNeuro: Availability of Documents and Information for the Annual Shareholders Meeting of May 27, 2021
Regulatory News:
GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neurologic and autoimmune diseases, including multiple sclerosis, informs its shareholders that the Annual General Meeting will be held on Thursday May 27, 2021 at 9.30am at its head office, 3, chemin du Pré-Fleuri, 1228 Plan-les-Ouates, Geneva, Switzerland.
Based on article 27 of Ordinance 3 on Measures to combat the Coronavirus of 19 June 2020 (COVID-19 Ordinance 3, status as of May 1st, 2021), the Board of Directors has decided that shareholders of the Company may exercise their rights at this Ordinary General Meeting exclusively through the Independent Proxy. This measure allows the Company to hold the Ordinary General Meeting as planned despite the pandemic. The conduct of the Ordinary General Meeting remains subject to additional measures issued by the